Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market

BTIG analyst Jeet Mukherjee maintained a Buy rating on Kymera Therapeutics today and set a price target of $138.00.

Jeet Mukherjee has given his Buy rating due to a combination of factors that highlight Kymera’s competitive position in the emerging oral atopic dermatitis market. He believes KT-621, Kymera’s STAT6 degrader, stands out versus new entrants like Corvus’s soquelitinib by offering stronger mechanistic validation through the well-established IL-4/IL-13 pathway and a more compelling biomarker profile. KT-621 demonstrated deeper modulation of key inflammatory and pruritus-related markers such as TARC and IL-31, alongside robust improvements in itch and quality-of-life measures, suggesting more comprehensive disease control.
At the same time, Mukherjee views Kymera’s safety thesis as more attractive over the long term, as STAT6 targeting avoids the mechanistic concerns inherent to ITK inhibition, including potential risks around EBV-related complications, lymphoproliferation, and recurrent infections with chronic use. He also notes that, while soquelitinib’s early EASI efficacy is encouraging, the limited itch and biomarker data leave open questions about durability and depth of response relative to KT-621. With Kymera advancing its phase 2b BROADEN2 trial toward a key 2027 data readout and supported by a valuation framework using a 12% discount rate and 2% terminal growth rate, Mukherjee sees an attractive risk-reward profile that supports a Buy recommendation on KYMR shares.

In another report released on January 30, Citi also maintained a Buy rating on the stock with a $110.00 price target.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is neutral on the stock.